Tempest therapeutics inc TPST.US 總覽分析

TPST 投資分析

TPST 近期報酬表現

與 TPST 同產業的標的表現

• PCSA Processa pharmaceuticals inc

  價值 2 分趨勢 1 分波段 4 分籌碼 1 分股利 1 分

  查看更多
• ACXP Acurx pharmaceuticals inc
• INBX Inhibrx biosciences inc
• TEM Tempus ai inc
• BCAX Bicara therapeutics inc
• BOLD Boundless bio inc
• RAPP Rapport therapeutics inc
• CGON Cg oncology inc
• CAMP Camp4 therapeutics corp
• ARTV Artiva biotherapeutics inc

TPST 公司資訊

Tempest Therapeutics Inc. Tempest Ther apeutics, Inc. is a clinical-stage biotechnology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a range of tumors. Its two clinical-stage therapeutic product candidates are Amezalpat and TPST-1495. Amezalpat is an oral, small molecule, selective antagonist of peroxisome proliferator-activated receptor alpha. The ongoing global randomized Phase Ib/II trial of Amezalpat combined with the standard-of-care first-line regimen of atezolizumab and bevacizumab in patients with advanced or metastatic hepatocellular carcinoma. The Company's second clinical program, TPST-1495, a dual antagonist of the EP2 and EP4 receptors of prostaglandin E2, a pathway implicated in multiple cancers.